ERBB2 and breast neoplasm: Tests in cell lines bearing these mutations showed that the tumour cells were more resistant to lapatinib than to neratinib, suggesting that neratinib might be a useful therapy for patients whose breast tumours bear these particular mutations in the HER2 gene.